RGX-104 + pembrolizumab + carboplatin + pemetrexed

This is a **combination regimen** consisting of: - **RGX-104**: An orally administered small molecule agonist of Liver X Receptor (LXR), which modulates innate immunity via activation of the ApoE gene. RGX-104 depletes myeloid-derived suppressor cells (MDSC), inhibits tumor angiogenesis, and enhances T-cell activation, potentially overcoming resistance to immunotherapy and chemotherapy. - **Pembrolizumab**: A monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor, acting as a checkpoint inhibitor to activate T-cells against tumor cells. - **Carboplatin**: A platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. - **Pemetrexed**: An antifolate chemotherapeutic agent that inhibits several enzymes necessary for purine and pyrimidine synthesis, thereby blocking DNA and RNA synthesis in tumor cells. This combination is under investigation, particularly for the treatment of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), including patients who are refractory to checkpoint inhibitors or have PD-L1-negative tumors[4].